1 National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;
| 2 Cancer patient, survivor, and patient advocate, Arlington, Virginia;
| 3 The Ohio State University Wexner Medical Center and Health Science Colleges, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, Ohio; and
| 4 The University of Texas MD Anderson Cancer Center, Dallas, Texas.
Health policy in America has shifted rapidly over the last decade, and states are increasingly exercising greater authority over health policy decision-making. This localization and regionalization of healthcare policy poses significant challenges for patients with cancer, providers, advocates, and policymakers. To identify the challenges and opportunities that lay ahead of stakeholders, NCCN hosted the 2019 Policy Summit: The State of Cancer Care in America on June 27, 2019, in Washington, DC. The summit featured multidisciplinary panel discussions to explore the implications for access to quality cancer care within a shifting health policy landscape from a patient, provider, and lawmaker perspective. This article encapsulates the discussion from this NCCN Policy Summit.
Submitted December 12, 2019; accepted for publication January 29 2020.
Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Correspondence: Terrell Johnson, MPA, National Comprehensive Cancer Network, 3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462. Email: firstname.lastname@example.org
Shifting regulatory authority from the federal government to states and the implications for patient access to high quality cancer care. Panel discussion at the NCCN Policy Summit: The State of Cancer Care in America: The Impact of State Policy on Access to High-Quality Cancer Care; June 27, 2019; Washington DC.
United States Government Accountability Office. Medicaid demonstrations: evaluations yielded limited results, underscoring need for changes to federal policies and procedures. Accessed September 23, 2019. Available at: http://www.gao.gov
Trends in cancer care policy at the state level. Panel discussion at the NCCN Policy Summit: The State of Cancer Care in America: The Impact of State Policy on Access to High Quality Cancer Care; June 27, 2019; Washington, DC.
AdamsonBJ, CohenAB, EstevezM, . Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment [abstract]. J Clin Oncol 2019;37(Suppl):Abstract LBA1.10.1200/JCO.2019.37.18_suppl.LBA1)| false
Partnership to Improve Patient Care. Analysis finds ICER incorporates only 16% of feedback received from patient advocates into final value assessments. Accessed September 25, 2019. Available at: https://www.pipcpatients.org
WhiteN, PaceM. Is ICER our Robin Hood? The role of an independent HTA in the Sherwood Forest of US drug pricing. Accessed September 24, 2019. Available at: https://www.iconplc.com/
ZafarSY, PeppercornJM, SchragD,
. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist2013;18:381–390.
ZafarSY, PeppercornJM, SchragD, . The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 2013;18:381–390.10.1634/theoncologist.2012-027923442307)| false
LesserM. The evolving role of states in ensuring access to high quality cancer care. Keynote at the NCCN Policy Summit: The State of Cancer Care in America: The Impact of State Policy on Access to High Quality Cancer Care; June 27, 2019; Washington, DC.
SB 398. An act concerning penalties for failure to comply with provisions governing the use of step therapy for prescription drugs. Open States. Accessed September 10, 2019. Available at: https://openstates.org/ct/bills/2018/SB398/